mo:re
Germany
- Hamburg
- 01/04/2025
- Seed
- $2,485,277
Your new teammate in the lab! Our lab platform takes over tedious and error-prone manual tasks in 3D cell culture, aiming to replace animal studies. A standardised repository of protocols lets you set up new experiments within minutes. Our AI-based quality control provides real-time transparency on the state of your cell culture, allowing you to worry less and make well-informed decisions.
- Industry Biotechnology Research
- Website https://more.science/
- LinkedIn https://www.linkedin.com/company/more-lifesciences/
Related People
Lukas GaatsFounder
Germany -
Hamburg, Hamburg
Co-founder & CEO of mo:re, a biotechnology start-up building the new gold standard for organoid-based drug development by offering a lab platform that industrialises cell culture workflows.
Our platform of a lab robot and software replaces animal studies with AI-assisted cultivation of disease models on which new compounds can be tested in a standardised and high-throughput fashion. This enables scaling up experiments without compromising traceability and quality to bridge the gap between PoC and industry experiments.
Visit mo:re https://more.science
Healthfab | $2,100,000 | (May 5, 2026)
Kibu, Inc | $10,500,000 | (May 5, 2026)
Fun | $72,000,000 | (May 5, 2026)
Featherless AI | $20,000,000 | (May 5, 2026)
LakeFusion | $7,500,000 | (May 5, 2026)
Enzo Health | $20,000,000 | (May 5, 2026)
Barocal | $10,000,000 | (May 5, 2026)
Zapdos Labs | $500,000 | (May 5, 2026)
Creati AI | $20,000,000 | (May 1, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)
DISA Technologies, Inc. | $33,000,000 | (May 1, 2026)